2025年生物追踪器数据监测医疗保健ASCO前报告_73页_1mb

Biomedtracker ASCO 2025 Abstract Summary Report

Clinical Cancer Research: Trial Data Updates

Ziftomenib for Acute Myelogenous Leukemia (AML)

A phase Ib/II study (KOMET-001) evaluating ziftomenib monotherapy in combination with venetoclax showed promising clinical responses. In 112 patients, the overall response rate (ORR) was 35% (39/112) with a complete response/complete response with partial hematological recovery (CR/CRh) rate of 25% (28/112). Study findings demonstrated deep and durable responses in relapsed/refractory NPM1-mutant AML cases, with limited myelosuppression and a low rate of treatment discontinuation. Ziftomenib is well-tolerated with an overall 3% discontinuation rate.

Petosemtamab for Head and Neck Cancer

Updated data from a phase I/II trial (MCLA-158) combining petosemtamab and pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) showed a high objective response rate (ORR) of 63% in 43 evaluable patients. The trial demonstrated a durable response with a median duration of response not reached at the time of analysis. The drug combination with immunotherapy is being investigated for its potential in improving outcomes in high-risk patient populations.

Bavencio for Bladder Cancer

Newtop-line results from the JAVELIN Bladder Medley phase II trial combining avelumab (Bavencio) with sacituzumab govitecan showed a significant improvement in progression-free survival (PFS) compared to avelumab monotherapy. The median PFS for the combination was 11.17 months versus 3.75 months. Further investigation and ongoing studies are expected to validate and expand these findings.

This summary report highlights key clinical trial updates presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, assessing efficacy and safety of several investigational therapies across various cancer types. Each study provides valuable insights into treatment options and outcomes for specific patient populations.